Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $1,335 | 2 | 56.7% |
| Food and Beverage | $920.81 | 10 | 39.1% |
| Education | $99.99 | 1 | 4.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $840.00 | 1 | $0 (2024) |
| GENZYME CORPORATION | $579.78 | 2 | $0 (2023) |
| Janssen Biotech, Inc. | $259.70 | 3 | $0 (2024) |
| BeiGene USA, Inc. | $197.14 | 2 | $0 (2023) |
| Adaptive Biotechnologies Corporation | $108.84 | 1 | $0 (2023) |
| Johnson & Johnson Health Care Systems Inc. | $106.68 | 1 | $0 (2024) |
| Seattle Genetics, Inc. | $99.99 | 1 | $0 (2019) |
| PFIZER INC. | $83.17 | 1 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $80.50 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,076 | 4 | Janssen Scientific Affairs, LLC ($840.00) |
| 2023 | $1,180 | 8 | GENZYME CORPORATION ($579.78) |
| 2019 | $99.99 | 1 | Seattle Genetics, Inc. ($99.99) |
All Payment Transactions
13 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Oncology | ||||||
| 09/24/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Food and Beverage | In-kind items and services | $109.54 | General |
| Category: Oncology | ||||||
| 07/23/2024 | Johnson & Johnson Health Care Systems Inc. | TECVAYLI (Biological), DARZALEX, TALVEY | Food and Beverage | In-kind items and services | $106.68 | General |
| Category: Oncology | ||||||
| 05/21/2024 | Janssen Scientific Affairs, LLC | DARZALEX (Drug) | Consulting Fee | Cash or cash equivalent | $840.00 | General |
| Category: Oncology | ||||||
| 08/16/2023 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, CARVYKTI | Food and Beverage | In-kind items and services | $130.16 | General |
| Category: Oncology | ||||||
| 08/08/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $84.78 | General |
| Category: Oncology | ||||||
| 05/22/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Consulting Fee | Cash or cash equivalent | $495.00 | General |
| Category: Oncology | ||||||
| 04/05/2023 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $108.84 | General |
| Category: ONCOLOGY | ||||||
| 03/29/2023 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $80.50 | General |
| Category: Hematology | ||||||
| 03/02/2023 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $83.17 | General |
| 01/12/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $98.57 | General |
| Category: Oncology | ||||||
| 01/12/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $98.57 | General |
| Category: Oncology | ||||||
| 11/06/2019 | Seattle Genetics, Inc. | — | Education | In-kind items and services | $99.99 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 366 | 639 | $184,815 | $45,170 |
| 2022 | 3 | 101 | 139 | $38,175 | $9,717 |
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 91 | 199 | $59,643 | $14,468 | 24.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 25 | 119 | $34,868 | $10,999 | 31.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 69 | 98 | $19,834 | $4,120 | 20.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 28 | 62 | $12,640 | $3,810 | 30.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 36 | 36 | $16,715 | $3,561 | 21.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 26 | 27 | $10,566 | $2,626 | 24.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 12 | 13 | $7,424 | $1,751 | 23.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2023 | 20 | 20 | $6,060 | $1,159 | 19.1% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 14 | 16 | $3,280 | $1,004 | 30.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 33 | 37 | $4,509 | $991.44 | 22.0% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2023 | 12 | 12 | $9,276 | $680.20 | 7.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 36 | 66 | $19,602 | $5,092 | 26.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 50 | 58 | $11,658 | $3,030 | 26.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 15 | 15 | $6,915 | $1,595 | 23.1% |
About Dr. Hashim Mann, MD
Dr. Hashim Mann, MD is a Hematology & Oncology healthcare provider based in Richmond, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/13/2016. The National Provider Identifier (NPI) number assigned to this provider is 1912350026.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Hashim Mann, MD has received a total of $2,356 in payments from pharmaceutical and medical device companies, with $1,076 received in 2024. These payments were reported across 13 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($1,335).
As a Medicare-enrolled provider, Mann has provided services to 467 Medicare beneficiaries, totaling 778 services with total Medicare billing of $54,888. Data is available for 2 years (2022–2023), covering 14 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Richmond, VA
- Active Since 07/13/2016
- Last Updated 08/04/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1912350026
Products in Payments
- DARZALEX (Drug) $840.00
- SARCLISA (Biological) $579.78
- TECVAYLI (Biological) $236.22
- BRUKINSA (Drug) $197.14
- DARZALEX (Biological) $130.16
- clonoSEQ (Device) $108.84
- Pomalyst (Drug) $80.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Richmond
Dr. Victor Yazbeck, M.d, M.D
Hematology & Oncology — Payments: $390,374
Attique Samdani, M.d, M.D
Hematology & Oncology — Payments: $146,382
Dr. Elke Friedman, Md, MD
Hematology & Oncology — Payments: $25,274
Dr. Asit Paul, M.d., Ph.d.,, M.D., PH.D.,
Hematology & Oncology — Payments: $7,490
Dr. Ghulam Qureshi, M.d, M.D
Hematology & Oncology — Payments: $7,032
Gisa-Beate Schunn, M.d, M.D
Hematology & Oncology — Payments: $5,929